The financial commitment features construction of new warehouses in Pennsylvania and North Carolina.
DHL Supply Chain, a logistics company that operates within Deutsche Post DHL Group, has made a $200 million investment toward growing its life sciences and healthcare offerings.1 This decision features the construction of new, state-of-the-art warehouse facilities in Pennsylvania and North Carolina, expanding their footprint to over 13 million square feet. The company will also be financially committing to the creation of warehouse technology that is expected to enhance operations and boost resiliency, specifically when it comes to battling unexpected disruptions.
When it comes to the life sciences, DHL Supply Chain currently has 35 warehouse facilities dedicated to this niche. With the new investment, that number is expected to grow to 40 sites by the end of 2024.
“Resilient life sciences and healthcare supply chains are critical to the well-being of communities around the world,” said Jim Saponaro, DHL Supply Chain’s president of life sciences and healthcare who recently participated in Pharma Commerce’s roundtable2 on third-party logistics (3PL) providers. “This significant investment reflects our commitment to providing the industry with the reliable, efficient, and temperature-controlled logistics solutions that’s needed to deliver life-saving treatments and products to patients in need.”
Various examples of the new warehouse technologies that clients should be expecting include:
References
1. DHL Supply Chain Announces $200 Million Investment in Life Sciences and Healthcare Logistics Expansion. DHL Supply Chain. February 13, 2024. Accessed February 16, 2024. https://www.dhl.com/us-en/home/press/press-archive/2024/dhl-supply-chain-announces-200-million-dollars-investment-in-life-sciences-and-healthcare-logistics-expansion.html
2. Saraceno, Nicholas. Peeking Behind the Curtain: The Current State of Pharma 3PLs and Future Outlook. Pharmaceutical Commerce. February 2, 2024. Accessed February 16, 2024. https://www.pharmaceuticalcommerce.com/view/peeking-behind-the-curtain-the-current-state-of-pharma-3pls-and-future-outlook
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.